Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Exportin-1

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1949

1

1997

1

2017

2

2019

2

2020

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute myeloid leukemia

1

Acute myeloid leukemia (relapsed/refractory)

1

Breast cancer

1

Cervical cancer

1

Dedifferentiated liposarcoma

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Karyopharm Therapeutics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

4

Structurally Diverse

3

Chemical

1

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

DAILYMED

9

FDA ORPHAN DRUG

9

FDA UNII

9

INN

9

NCI_THESAURUS

9

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

BLOOD AND BLOOD FORMING ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

OTHER HEMATOLOGICAL AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

1

OTHER HEMATOLOGICAL AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Enzymes

1

Monoclonal antibodies

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

8

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated/Approved|Treatment of diffuse large B-cell lymphoma" in comments (approximate match)

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

HYALURONIDASE (BOVINE)

8KOG53Z5EM

Status:

US Approved Rx (2004)

First approved in 1949

Class:

MIXTURE

LONCASTUXIMAB TESIRINE

7K5O7P6QIU

Subunit 1 (449) Similarity Search Subunit 2 (449) Similarity Search Subunit 3 (211) Similarity Search Subunit 4 (211) Similarity Search

Export Data
Sequence Search

Subunit 1 (449) Similarity Search Subunit 2 (449) Similarity Search Subunit 3 (211) Similarity Search Subunit 4 (211) Similarity Search

Status:

US Approved Rx (2021)

First approved in 2021

Class:

PROTEIN

TAFASITAMAB

QQA9MLH692

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (219) Similarity Search Subunit 4 (219) Similarity Search

Export Data
Sequence Search

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (219) Similarity Search Subunit 4 (219) Similarity Search

Status:

US Approved Rx (2020)

First approved in 2020

Class:

PROTEIN

POLATUZUMAB VEDOTIN

KG6VO684Z6

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Export Data
Sequence Search

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Status:

US Approved Rx (2019)

First approved in 2019

Class:

PROTEIN

RITUXIMAB

4F4X42SYQ6

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Export Data
Sequence Search

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Status:

US Approved Rx (2020)

First approved in 1997

Class:

PROTEIN

AXICABTAGENE CILOLEUCEL

U2I8T43Y7R

Status:

US Approved Rx (2017)

First approved in 2017

Class:

STRUCTURALLY DIVERSE

TISAGENLECLEUCEL

Q6C9WHR03O

Status:

US Approved Rx (2017)

First approved in 2017

Class:

STRUCTURALLY DIVERSE

LISOCABTAGENE MARALEUCEL

7K2YOJ14X0

Status:

Possibly Marketed Outside US

First approved in 2021

Class:

STRUCTURALLY DIVERSE

SELINEXOR

31TZ62FO8F

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2019

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Multiple myeloma

Acute myeloid leukemia

Acute myeloid leukemia (relapsed/refractory)

Cervical cancer

Dedifferentiated liposarcoma

Endometrial cancer

Selinexor (KPT-330) is a first in class XPO1 antagonist being evaluated in multiple later stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1